Prime Medicine, Inc. (PRME)
Last updated: 2026-10-20 20:23:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Prime Medicine, Inc. (PRME) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $3.94, with a market capitalization of $629.38M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.67 to $6.30. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$629.38M | |
$3.75 | |
$21.73 | |
$1.11 | |
$3.83 | |
3.34M | |
3.48M | |
-- | |
$6.30 | |
$2.67 | |
-- | |
-- |
Prime Medicine, Inc. (PRME) After-Hours Stock Price
Prime Medicine, Inc. (PRME) is trading at $3.96 in after-hours trading as of 2026-10-20 20:19:00, up 3.29% ($0.13) from the regular-session close of $3.83.
After-hours trading shows how investors are pricing PRME after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Prime Medicine, Inc. (PRME) 7-Day Stock Price Change
Over the past seven days, Prime Medicine, Inc. (PRME) moved from $3.99 to $3.94, representing a decline of 1.38% ($0.06).
The stock traded between $3.05 and $4.14 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 4.92 million shares, down versus the previous seven-day period, indicating lower trading activity.
PRME 52-Week Price Position
Position in Range: 34.8%
PRME is currently trading at $3.94, placing it 34.8% of the way from its 52-week low of $2.67 to its 52-week high of $6.30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Prime Medicine, Inc. (PRME)?
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Prime Medicine, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 146 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Prime Medicine, Inc. (PRME) Stock on MEXC
Eligible investors can buy real shares of Prime Medicine, Inc. (PRME) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Prime Medicine, Inc. (PRME) stock price today?
2.Is PRME stock going up or down today?
3.What is PRME pre-market price?
4.What is PRME after-hours price?
5.Is PRME stock trading now?
6.Where does PRME sit relative to its 52-week high and low?
7.What sector is Prime Medicine, Inc. in?
8.What is Prime Medicine, Inc.'s market capitalization and where is it listed?
9.How is PRME valued in terms of P/E ratio and EPS?
10.Does Prime Medicine, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
PRME Stock Calculator
Estimate the value between PRME shares and USD.
PRME Shares to USD
1.00 PRME shares = 3.935 USD
Calculations are estimates based on the latest available price and are for reference only.


